Category Archives: Parkinson’s Treatment

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/5zvqz8/neurodegenerative) has announced the addition of the "Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff" report to their offering. GBI Research, the leading business intelligence provider, has released its latest research Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff. A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer's disease has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products. The market for Parkinson's disease, on the other hand, is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it will soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly. … Continue reading →

Alzheimer's, Dementia & Mental Health Parkinsons Drug Helps Seniors in Their Seventies With Decision-Making Discover brain activity of senior citizens is different than in young adults who are better at making decisions March 25, 2013 - New research finds changes in the patterns of brain activity of senior citizens in their seventies offers new insight into why the elderly are worse at decision-making than young people and they also discover a Parkinsons Disease drug can help reverse age-related impairments in decision-making in older people. The study from researchers at the Wellcome Trust Centre for Neuroimaging, London, England, is published today in the journal Nature Neuroscience. Poorer decision-making is a natural part of the aging process that stems from a decline in our brains' ability to learn from our experiences. Part of the decision-making process involves learning to predict the likelihood of getting a reward from the choices that we make. An area of the brain called the nucleus accumbens is responsible for interpreting the difference between the reward that we're expecting to get from a decision and the reward that is actually received. These so called 'prediction errors', reported by a brain chemical called dopamine, help us to learn from … Continue reading →

deepbrainstimulationforparkinsons By: Paul Kieffaber … Continue reading →

6PR talkback host Howard Sattler has recently been diagnosed with Parkinson's disease. Source: News Limited RADIO veteran Howard Sattler isn't the type of person to do anything quietly, let alone die quietly. So the 6PR talkback host has vowed to fight tooth and nail to stay on air despite being recently diagnosed with Parkinson's disease. In an effort to spread awareness and support research for Parkinsons, Sattler has opened up about how he is battling the condition and what keeps him fighting. Howard Sattler wakes suddenly. It is dark and he is terrified - a feeling he has become familiar with over the past few months. The fog of dreams and nightmares clears and he remembers where he is. He's in a situation he does not want to be in, doing things he does not want to do. It's hard, it's frightening and it's a battle he can only fight on his own. There is one thing keeping him going - fear. Fear of the alternative. Fear of what will happen to him if he gives up. "Get up," Sattler urges himself. "If I don't get through this I'm going to get shot dead in the middle of a jungle." … Continue reading →

The head of Parkinson's Australia says Radio 6PR talkback host Howard Sattler was "brave" to publicly open up about his battle with the disease. The famously polarising Sattler told Perth's Sunday Times that he had been undergoing treatment for Parkinson's since last year, after suffering what was diagnosed as a stroke last May. Parkinson's Australia Daryl Smeaton said it was admirable for a media figure such as Sattler to discuss his disease openly. "I think Howard is very brave to come out about being diagnosed," Smeaton said. Advertisement "It's important for people to understand that even though it's incurable, you can still have a good quality of life." Sattler said he visited a number of doctors over the past two years, prompted when his speech began to slur and radio listeners accused him of being drunk on air - leading 6PR management to intervene. "I was talking Swahili," Howard said. "It got to the stage where no one could understand me." Sattler said a specialist finally told him that he had the disease in June. Go here to see the original: Sattler 'brave' in Parkinson 's battle … Continue reading →

Parkinson's Disease Treatment: Balance and Walking (Gait) Improve with TMJ Treatment Dr. Demerjian helps improve his Parkinson's symptoms of Gait and Balance with a custom TMJ mouth piece. TMJ/ Parkinson's connection. Also included is his one... By: Gary Demerjian … Continue reading →

$1 MM grant by The Michael J. Fox Foundation to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson`s disease levodopa-induced dyskinesia Geneva, Switzerland, 21 March 2013 - Addex Therapeutics (ADXN.SW), a leading company pioneering allosteric modulation-based drug discovery and development announced today that Franois Tison, M.D.-Ph.D., Professor at the University of Bordeaux, on behalf of the ADX48621-201 Study Group, presented the positive data obtained from a Phase 2a proof-of-concept trial of dipraglurant (ADX48621) in Parkinson`s patients with levodopa-induced dyskinesia (PD-LID) in an oral presentation at the AAN conference on 20th March 2013. The recent $1,000,000 grant by The Michael J. Fox Foundation for Parkinson`s Research will be used to help fund continued human clinical testing of dipraglurant for the treatment of PD-LID. One-third of people with PD develop dyskinesia within four to six years of beginning levodopa treatment; this increases to approximately 90 percent after nine or more years. Patients with Parkinson`s disease (PD) can live 10-20 years after diagnosis; however, PD-LID is a leading cause of disability in this growing patient population. "We believe the successful completion of the Phase 2a study showed significant promise that dipraglurant has the potential to … Continue reading →

CARLSBAD, CA--(Marketwire - Mar 19, 2013) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells announced today safety and encouraging efficacy of stem cell therapy in rodent and non-human primate models of Parkinson's disease. "This pilot study represents a first essential step in bringing cell-based therapies for Parkinson's disease to clinical trials," commented co-author of the study Evan Y. Snyder, MD, PhD, Director of Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute. These placebo-controlled studies were designed to demonstrate the viability, fate and functional efficacy of the stem cell derived neural cells after implantation to the brain.Highly pure populations of neuronal cells were differentiated from human parthenogenetic stem cells (hpSC) according to the protocol developed by International Stem Cell Corporation and recently published in the Nature Publishing Group's Scientific Reports. The studies employ MPTP-lesioned African Green monkeys and 6-OHDA-lesioned rats, the principle models used to study Parkinson's disease.The duration of the primate study was four months and the rodent study six months.In the non-human primate model, behavioral endpoints were assessed with parkinsonian scores. These scores, based on a standardized rating … Continue reading →

One of the most promising new approaches to treating Parkinsons disease hit a snag after researchers found early evidence it may make people worse. The experimental technique involves reducing levels of alpha-synuclein, a protein found in clumps in the brains of people with Parkinsons that increases the risk of the disease. Research presented at the American Academy of Neurology meeting in San Diego shows the condition progresses more rapidly in patients with naturally low levels of the protein. Companies including Elan Corp., Alnylam Pharmaceuticals Inc. (ALNY), NeuroPhage Pharmaceuticals Inc. and Prana Biotechnology Ltd. (PBT) have early-stage efforts under way to develop drugs aimed at alpha-synuclein. The Michael J. Fox Foundation has put more than $47 million into research targeting the protein. The results suggest patients in clinical trials to lower alpha- synuclein may be at risk, said Demetrius Maraganore, a study author. There is a sense of urgency related to their safety, Maraganore, who is chairman of neurology at NorthShore University Health System in Evanston, Illinois, said in a telephone interview. If this work is reproducible and our interpretation of the findings is correct, this has immediate relevance to people with Parkinsons. The study released yesterday found patients with a … Continue reading →

ATLANTA, March 19, 2013 /PRNewswire/ --UCB today announced data from a non-interventional, observational study conducted in Germany that found that when Parkinson's disease (PD) patients were switched from an oral PD medication to Neupro (Rotigotine Transdermal System), they reported improvements in pre-existing gastrointestinal (GI) symptoms. The data were presented at the American Academy of Neurology's (AAN) 2013 Annual Scientific Meeting in San Diego, March 16-23, 2013. "GI symptoms are common non-motor symptoms in PD patients, and can significantly affect their daily life," said Dirk Woitalla, MD, lead study author, St. Josef-Hospital Universitatsklinik. "The findings presented at AAN show the potential improvement rotigotine may have on these symptoms for people living with PD. Controlled clinical studies are needed to confirm this finding." In the study conducted in a clinical practice setting in Germany, PD patients experiencing GI symptoms (e.g., heartburn, bloating, nausea, vomiting, abdominal pain or diarrhea) while receiving oral drug treatment were switched by their physician to rotigotine transdermal system.1 Primary efficacy outcomes included changes in GI symptoms (measured by a visual analogue scale [intensity; 0-100 mm]) and the sum score of GI complaints (six items each rated 0-12 for sum of 0-72), in addition to patient satisfaction in relation … Continue reading →